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Introduction: Physical inactivity and overweight are risk factors for postmenopausal breast cancer. The effect of
physical activity may be partially mediated by concordant weight loss. We studied the effect on serum sex
hormones, which are known to be associated with postmenopausal breast cancer risk, that is attributable to
exercise by comparing randomly obtained equivalent weight loss by following a hypocaloric diet only or mainly by
exercise.
Methods: Overweight, insufficiently active women were randomised to a diet (N = 97), mainly exercise
(N = 98) or control group (N = 48). The goal of both interventions was to achieve 5–6 kg of weight loss by
following a calorie-restricted diet or an intensive exercise programme combined with only a small caloric
restriction. Primary outcomes after 16 weeks were serum sex hormones and sex hormone-binding globulin
(SHBG). Body fat and lean mass were measured by dual-energy X-ray absorptiometry.
Results: Both the diet (−4.9 kg) and mainly exercise (−5.5 kg) groups achieved the target weight loss. Loss of body
fat was significantly greater with exercise versus diet (difference −1.4 kg, P < 0.001). In the mainly exercise arm, the
reduction in free testosterone was statistically significantly greater than that of the diet arm (treatment effect ratio
[TER] 0.92, P = 0.043), and the results were suggestive of a difference for androstenedione (TER 0.90, P = 0.064) and
SHBG (TER 1.05, P = 0.070). Compared with the control arm, beneficial effects were seen with both interventions, diet
and mainly exercise, respectively, on oestradiol (TER 0.86, P = 0.025; TER 0.83, P = 0.007), free oestradiol (TER 0.80,
P = 0.002; TER 0.77, P < 0.001), SHBG (TER 1.14; TER 1.21, both P < 0.001) and free testosterone (TER 0.91, P = 0.069;
TER = 0.84, P = 0.001). After adjustment for changes in body fat, intervention effects attenuated or disappeared.
Conclusions: Weight loss with both interventions resulted in favourable effects on serum sex hormones, which have
been shown to be associated with a decrease in postmenopausal breast cancer risk. Weight loss induced mainly by
exercise additionally resulted in maintenance of lean mass, greater fitness, greater fat loss and a larger effect on (some)
sex hormones. The greater fat loss likely explains the observed larger effects on sex hormones.
Trial registration: ClinicalTrials.gov identifier: NCT01511276. Registered on 12 January 2012.* Correspondence: e.monninkhof@umcutrecht.nl
1Department of Epidemiology, Julius Centre for Health Sciences and Primary
Care, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht,
The Netherlands
Full list of author information is available at the end of the article
© 2015 van Gemert et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van Gemert et al. Breast Cancer Research  (2015) 17:120 Page 2 of 12Introduction
Obesity and physical inactivity are convincing risk fac-
tors for postmenopausal breast cancer, according to the
World Cancer Research Fund [1]. Together, these factors
contribute to approximately 15 % of breast cancer cases
that develop after menopause [2–4]. More important,
these are two of the few known lifestyle-related risk fac-
tors, and, therefore, exposure is modifiable. Because the
prevalence of both overweight or obesity and physical
inactivity in the Western world are increasing, this sub-
ject is an important one to consider in devising breast
cancer prevention strategies.
One of the pathways by which these lifestyle factors may
influence postmenopausal breast cancer risk is through ef-
fects on serum sex hormones (i.e., oestrogens, androgens
and the protein sex hormone-binding globulin [SHBG])
[5]. Observational, prospective studies have consistently
shown a higher breast cancer risk of up to twofold in post-
menopausal women with endogenous sex hormone levels
in the highest versus the lowest quintile [6, 7].
In a previous randomised controlled trial, the Sex
Hormones and Physical Exercise (SHAPE) study, we
assessed the effect of a 1-year physical activity interven-
tion on serum sex hormones in insufficiently active post-
menopausal women. In contrast to observational studies,
in which an effect of physical activity is often also ob-
served after adjustment for differences in body mass
index (BMI), we did not find an effect of exercise in the
SHAPE study. However, in a subgroup of women who
lost more than 2 % body fat, larger effects were observed
with exercise compared with the control group. These
results were supported by two other intervention studies
[8–10]. We hypothesised then that weight or fat loss is
essential for any beneficial effect of physical activity on
sex hormones. But the question remained whether it
was purely the weight loss that induced the beneficial ef-
fects on sex hormones or whether physical activity itself
contributed additionally to the breast cancer risk–lower-
ing effects. To answer this question, we designed the
SHAPE-2 study, in which we are investigating the effects
of an equivalent weight loss obtained by following a
hypocaloric diet or mainly with an exercise programme
[11]. We expect that adding exercise to diet–induced
weight loss will result in a more favourable body com-
position (i.e., a decrease in body fat mass and a preserva-
tion or increase of lean body mass) and thereby lead to
larger decreases in serum sex hormone levels compared
with equivalent diet-induced weight loss. Furthermore,
we hypothesise that exercise might have an effect on
serum hormone levels, independent of the body fat path-
way (e.g., via insulin and glucose). This hypothesis is also
based on results from observational studies in which ad-
justments for weight still show beneficial effects of phys-
ical activity on future breast cancer risk.Methods
Design and study population
The SHAPE-2 study is a three-armed, randomised con-
trolled trial in which postmenopausal women are allo-
cated to a diet-induced weight loss intervention, to a
combined diet- and exercise-induced weight loss inter-
vention or to a control group. The study ran from
February 2012 until June 2013 in eight municipalities in the
Netherlands. The study was approved by the ethics com-
mittee of the University Medical Centre Utrecht. Written
informed consent was obtained from all participants. De-
tails of the study design were reported previously [11].
Women, aged 50–69 years were recruited via mass
mailings and media publicity. Women who responded
were contacted by telephone by a study nurse to assess
their eligibility. Eligibility was checked again during a
screening visit at which weight and height were mea-
sured. Level of physical activity was further evaluated
during this screening visit by focusing on sports, means
of transportation and leisure time activities.
Women were eligible if they were postmenopausal
(>12 months since last menses), overweight or obese
(BMI 25–35 kg/m2) and insufficiently active (<2 h/wk of
≥4 metabolic equivalents [MET] activity) (Table 1). The
main exclusion criteria were smoking, diabetes, use of
exogenous (sex) hormones or ever diagnosed with breast
cancer (Table 1).
Run-in period, standardised diet and randomisation
All women started with a 4–6-week run-in period during
which a tailor-made, standardised diet was prescribed to
maintain stable weight and to achieve a comparable diet
composition among all study participants (50–60 % carbo-
hydrates, 15–20 % proteins, 20–35 % fat, minimum 25 g of
fibre, maximum of one alcoholic consumption/day) [12].
After baseline measurements, women were rando-
mised by using a computer programme, stratified for
municipality to a diet-induced weight loss group (diet
group; n = 97), a weight loss induced mainly by exercise
group (mainly exercise group; n = 98) or a stable weight
control group (control group; n = 48). The computer
programme contained an automatically generated ran-
dom sequence with block sizes of 5 (2:2:1 ratio of inter-
ventions to control).
Intervention and control group procedures
Both weight loss intervention programmes, which were
aimed at achieving a 5–6-kg weight loss, were delivered
by physiotherapists and/or dietitians, who also closely
monitored body weight by supervised weighing. When
participants reached the target weight loss, or after a
maximum of 14 weeks, they entered a period of weight
maintenance (2–6 weeks) wherein diet was adapted to
stabilise body weight.
Table 1 SHAPE-2 study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Female Presently using sex hormones
Age 50–69 yr Use of β-blockers or oral corticosteroids
Postmenopausal (>12 mo since last menses) Smoking
Body mass index (BMI) 25–35 kg/m2 Alcohol or drug abuse
Insufficiently active (<2 h/wk of at least moderately intensive activities (≥4 MET)) Diagnosed breast cancer (present or history)
Willing to be randomly assigned to one of the three study arms Diagnosed with other cancer (present or <5 yr of history),
except non-melanoma skin cancer
Informed consent for all screening and study activities Diabetes mellitus or other (unstable) endocrine-related diseases
Any disorder that might impede participation in the exercise
programme
Following, or intention to follow, a structured weight loss
programme elsewhere
Investigator’s opinion (i.e., successful fulfilling of the programme
highly unlikely)
Source: van Gemert et al. [11]
Abbreviations: MET metabolic equivalents, SHAPE Sex Hormones and Physical Exercise study
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throughout the study period. Women filled out 3-day
food diaries (in all three study groups), kept an exercise
log (only in the mainly exercise group), performed
weekly (only in the diet group) or biweekly (only in the
mainly exercise group) self-weighing and had frequent
contacts with their dietitian or physiotherapist (in the
diet and the mainly exercise groups).
Diet group
Women in the diet group were prescribed a caloric re-
striction of 3500 kcal/wk (or 500 kcal/day) as compared
with their estimated needs and habitual intake (standar-
dised diet during the run-in period). They were asked to
maintain their habitual physical activity levels. Individual
contacts with the dietitian included two individual con-
sultations of 30 minutes and telephone consultations
every other week for monitoring and motivation [13].
During these contacts, diet was assessed by dietary his-
tory and/or by checking the food diaries. The diet was
adjusted when needed. In addition, five 1-h group ses-
sions (maximum of 12 women/group) were scheduled to
provide nutritional education, self-management training
and behaviour change techniques.
Mainly exercise group
The mainly exercise group followed an intensive 4 h/wk
combined endurance and strength exercise programme.
These women also were prescribed a relatively small cal-
oric intake restriction of 1750 kcal/wk (250 kcal/day) to
ensure achievement of the 5–6-kg weight loss goal within
14 weeks. Because in this group the main focus was on ex-
ercise, we refer to this group as the ‘mainly exercise in-
duced weight loss’ or ‘mainly exercise’ group for short.The exercise programme included two 1-h group ses-
sions of combined strength and endurance training at
the physiotherapy centre and two 1-h sessions of moder-
ate to vigorous Nordic walking per week. Nordic Walk-
ing is a form of fitness walking enhanced by the addition
of walking poles. Compared to regular walking, Nordic
walking makes more use of the entire body resulting in
significant increases in energy expenditure.
For a 58-year-old woman, whose weight is 78 kg and
height is 1.65 m, corresponding to the average SHAPE-1
[9] participant with a BMI ≥25 kg/m2, the prescribed
four exercise sessions resulted in an average energy ex-
penditure of approximately 2530 kcal/wk based on cor-
rected MET values [14, 15]. The caloric restriction was
1750 kcal/wk. The total targeted weekly energy deficit
from exercise and diet in the mainly exercise group was,
therefore, approximately 4280 kcal/wk.
We chose a combination of aerobic exercise and strength
training because strength training leads to preservation of,
or even an increase in, muscle mass and bone mineral dens-
ity [16, 17]. This is important in postmenopausal women to
improve health and enable an active lifestyle. Furthermore,
we expected that strength training would support loss of
body fat by increasing the basic metabolic rate [18].
Group sessions included 20–25 minutes of endurance
training, 25 minutes of strength training and 5–10-minute
warm-ups and cool-downs. Heart rate monitors were worn
while exercising. Training intensity was gradually increased
during the study: for endurance training, from 60 % to 90
% of the heart rate reserve [HRR]), and for strength train-
ing, based on repetition maximum tests. The 1-h Nordic
walking sessions were performed at 60–65 % of HRR.
Women were strongly encouraged to join supervised
classes given by a Nordic walking instructor. However,
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form these sessions without guidance. Furthermore,
women were instructed to increase their energy expend-
iture in daily activities, for example by taking the bike
for shopping and by climbing stairs.
Participants kept an exercise log that the physiotherap-
ist regularly checked.
Losing substantial weight just by increasing physical
activity levels is difficult [19]. Other studies have shown
that compensatory mechanisms, both physically and
mentally, withhold persons from losing weight [20, 21].
To ensure substantial weight loss, a dietitian-prescribed
caloric restriction of 1750 kcal/wk was added to the
exercise programme [20]. The targeted total average
weekly deficit for the mainly exercise group was larger
than that for the diet group (4280 kcal vs 3500 kcal) to
compensate for the gain in muscle mass (i.e., body weight)
induced by the combined endurance and strength exercise
programme.
Control group
Women in the control group were asked to maintain a
stable weight by continuing to follow the standardised
diet and their habitual physical activity patterns. To keep
them from starting any attempts to lose weight during
the study period, women in the control group were of-
fered an alternative exercise weight loss programme to
be started after study completion.
Outcome measurements
Outcomes were measured at baseline (i.e., before ran-
domisation) and at 16 weeks after baseline. Body weight,
height and waist and hip circumferences were measured
according to standard procedures by trained study
personnel [11]. Fat and lean mass were assessed by
whole-body dual-energy X-ray absorptiometry (DEXA)
(Lunar iDXA, Prodigy; GE Healthcare, Little Chalfont,
UK). Cardiorespiratory fitness (according to peak oxygen
uptake [VO2peak]) was measured by having the women
perform a maximal cycle exercise test during which re-
spiratory gas analysis was done using a ramp protocol.
Physical activity was measured by administering the
Short Questionnaire to Assess Health-Enhancing Phys-
ical Activity (SQUASH) [22] and objectively during 7
consecutive days by having the women wear a GT3X+ ac-
tivity monitor (ActiGraph, Pensacola, FL, USA) [23, 24].
Serum sex hormone analyses
Participants were asked not to perform moderate to vig-
orous physical activity in the 48 h preceding the blood
sampling. Serum was collected and stored at −80 °C.
After trial completion, all samples were sent, frozen, to
the laboratory for analyses. Multiple samples from each
individual were analysed in the same batch. Oestradiol,oestrone, androstenedione and testosterone levels were
determined by liquid chromatography–mass spectrom-
etry (LC-MS) [25] in the University Hospital of South
Manchester laboratory, Manchester, UK. Free fractions
of oestradiol and testosterone were calculated by using
the total hormone levels, SHBG and a constant for albu-
min [26]. SHBG was measured by using commercially
available double-antibody radioimmunoassay kits (SHBG-
03052001, cobas; Roche Diagnostics, Burgess Hill, UK).
The assays were performed in the SHO Velp laboratory,
Velp, The Netherlands. Inter- and intra-class coefficients
of variation were <10 % for androgens [27], <7 % for
oestrogens [28] and <2 % for SHBG. Technicians were
blinded to study allocation.
Hormone values below the lower limit of detection
were assigned the value of this limit (i.e., 1.4 pg/ml for
oestrone [n = 16] and 86 pg/ml for testosterone [n = 24]
and androstenedione [n = 1]). Six oestradiol measures
outside acceptable postmenopausal values (>42 pg/ml)
and accompanying oestrone levels were excluded from
analyses (five at baseline and one at follow-up).
Statistical analyses
We calculated that 104 women in both intervention
groups and 45 women in the control group were re-
quired to detect a difference of at least 8 % in oestradiol
levels between the two intervention groups (primary
comparison; two-sided α 0.05), and a 12–20 % decrease
versus control (secondary comparison; two-sided α 0.025)
with 80 % power.
The primary analysis was done according to the
intention-to-treat principle. Outcomes are based on
complete cases [29] (i.e., both baseline and follow-up mea-
surements). Between-group differences in outcomes, ad-
justed for baseline sex hormone levels, were computed by
linear regression. Hormones were log-transformed;
therefore, their coefficients with 95 % confidence inter-
vals (95 % CIs) represent a treatment effect ratio (TER) that
indicates how many times the level in one group is higher
(TER >1) or lower (TER <1) than the reference group.
Secondary analyses were performed in (1) women who
reached >2-kg weight loss in the intervention groups
and stable weight (±2 kg) in the control group and (2)
women who adhered to the exercise goal (i.e., for the
mainly exercise group, >80 % attendance; for the diet
and control groups, <60-minute increase in leisure time
activities of ≥4 MET/wk, according to the SQUASH
questionnaire or, if missing, ActiGraph activity monitor).
IBM SPSS statistical software (version 20; IBM, Armonk,
NY, USA) was used for the analyses.
Results
Women in the intervention and control groups were
comparable in baseline characteristics (Table 2). Study
Table 2 Baseline characteristics of the SHAPE-2 study population
Control group Diet group Mainly exercise group
(n = 48) (n = 97) (n = 98)
Mean (SD)
Age (yr) 60.0±4.9 60.5±4.6 59.5±4.9
Time since last menses (yr) 11.4±7.8 10.7±6.1 10.9±7.7
Education level,a n (%)
Low 15 (31.3 %) 27 (27.8 %) 33 (33.6 %)
Middle 15 (31.3 %) 27 (27.8 %) 20 (20.4 %)
High 18 (37.5 %) 42 (43.3 %) 44 (44.9 %)
First-degree family member(s) with breast cancer, n (%) 9 (18.8 %) 23 (23.7 %) 24 (24.5 %)
Anthropometrics
Weight (kg) 80.9±10.0 80.0±8.6 80.4±9.0
BMI (kg/m2) 29.5±2.6 29.3±2.5 29.0±2.9
Waist circumference (cm) 99.0±8.7 97.8±7.5 97.5±8.3
Hip circumference (cm) 110±7.7 110±6.8 109±6.7
Body composition measured by DEXA
Body fat percentage (%) 43.6±5.0 44.1±3.8 43.8±4.0
Total body fat (kg) 34.2±7.4 33.9±5.7 33.9±6.2
Lean mass (kg) 43.4±3.9 42.7±4.0 43.1±4.1
Physical fitness and activity
VO2peak, relative (ml/kg/min) 22.1±4.7 21.9±4.0 21.8±3.7
VO2peak (ml/min) 1751±363 1742±310 1749±293
Physical activity monitor (min/day)b Median (IQR)
Sedentary 652 (600–691) 637 (606–685) 630 (593–678)
Light 179 (164–226) 194 (175–214) 197 (157–229)
Moderate 35 (25–39) 35 (22–46) 33 (27–46)
Vigorous 0.33 (0.17–0.61) 0.35 (0.17–0.53) 0.29 (0.14–0.47)
SQUASH moderate and vigorous activityc (min/wk) 270 (120–495) 184 (115–420) 248 (90–465)
Alcohol (g/day) 3.7 (0.0–11.7) 5.7 (0.0–10.0) 4.3 (0.0–10.0)
Geometric mean (95 % CI)
Oestradiol (pg/ml) 4.10 (3.51–4.79) 4.15 (3.67–4.70) 3.70 (3.33–4.12)
Oestrone (pg/ml) 21.0 (18.4–24.0) 20.4 (18.9–22.0) 19.3 (17.7–21.1)
Free oestradiol (pg/ml) 0.10 (0.08–0.12) 0.10 (0.08–0.11) 0.09 (0.08–0.10)
Testosterone (pg/ml) 201 (174–233) 196 (178–215) 183 (167–200)
Androstenedione (pg/ml) 593 (508–692) 561 (508–620) 556 (497–622)
Free testosterone (pg/ml) 2.78 (2.36–3.28) 2.54 (2.31–2.79) 2.41 (2.21–2.63)
SHBG (nmol/L) 45.1 (39.7–51.3) 50.1 (45.7–55.0) 48.8 (44.7–53.3)
Data on family history of breast cancer were available for 241 women (99.2 %), DEXA scan measurements for 240 women (98.8 %), VO2peak for 237 women (97.5 %),
alcohol intake for 226 women (93.0 %), SQUASH questionnaires for 236 (97.1 %) women and accelerometer data for 161 of 215 women (74.9 %). All hormone levels
were missing for one woman, and (free) oestradiol, (free) testosterone and androstenedione were also missing for one woman. Five baseline values for (free) oestradiol
and oestrone were excluded (>42 pg/ml). All other data were available for all women (N = 243)
Abbreviations: BMI body mass index, CI confidence interval, DEXA dual-energy X-ray absorptiometry, IQR interquartile range, SD standard deviation, SHAPE Sex
Hormones and Physical Exercise study, SHBG sex hormone-binding globulin, SQUASH Short Questionnaire to Assess Health-Enhancing Physical Activity, VO2peak
peak oxygen uptake
aEducation levels: low = primary school and technical/professional school, middle = college degree, high = university degree
bGT3X+ ActiGraph activity monitor measuring minutes per day of activity spent in each activity category
cBased on the SQUASH physical activity questionnaire, activities performed ≥4 metabolic equivalents
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29.2 kg/m2, a mean body fat percentage of 44 % and a
mean VO2peak of 21.9 ml/kg/min, indicating poor phys-
ical fitness.
Of all the 243 participating women, 232 (95.5 %) com-
pleted the trial and 11 dropped out (three each in the
control and diet groups and five in the mainly exercise
group) (see Fig. 1). Complete data on weight, BMI, and
waist and hip circumferences were available for 232
women; fat mass (in kilograms and percent) and lean
mass for 230 women; VO2peak for 219 women; and
SQUASH data for 206 women. Blood samples of 230
women were available. The median number of group
sessions attended by women in the diet group was four
(out of five offered), and 70 % of women attended at
least four sessions. All women attended the first individ-
ual contact appointment with the dietitian for the
standardised diet prescription. Of the women in the
intervention groups, 98.4 % attended the individual con-
sultation with the dietitian for the intervention diet
prescription and 91.4 % attended the individual con-
sultation for maintenance diet prescription. All other
women received dietary prescriptions by post, which
were discussed by telephone. For the mainly exercise
group, the median attendance rates for the group exercise
sessions and Nordic walking training hours were 81 % and
88 %, respectively. Musculoskeletal injuries were reportedFig. 1 Flowchart of the inclusion, random assignment and follow-up of the
‘Dropouts’ refers to women who withdrew from the study before the end
‘Not received intervention as assigned’ refers to women who also withdrew f
DEXA dual-energy X-ray absorptiometryby 9 % in the control group, 5 % in the diet group and 15 %
in the mainly exercise group. No serious adverse events
occurred.
Body composition and fitness outcomes
After 16 weeks, the diet and mainly exercise groups ac-
complished average weight loss of −4.9 kg (−6.1 %) and
−5.5 kg (−6.9 %), respectively. The control group
remained weight-stable (0.06 kg [0.1 %]) (Table 3). All
anthropometric factors and body fat (in kilograms and
percent) showed statistically significant decreases in both
intervention groups versus the control group (Table 3).
Compared with the diet group, the mainly exercise
group showed a greater decrease in waist and hip cir-
cumferences; however, the differences were not statisti-
cally significant (respectively: −0.86 cm, 95 % CI −1.84
to 0.13; −0.36 cm, 95 % CI −1.15 to 0.44). Decreases in
body fat were statistically significantly greater in the
mainly exercise versus the diet group (respectively: −1.43
kg, 95 % CI −2.02 to −0.84; −1.56 %, 95 % CI −2.14 to
−0.98). Lean mass was preserved in the mainly exercise
group compared with control (0.02 kg, 95 % CI −0.42 to
0.46), whereas the diet group lost lean mass (−0.71, 95 %
CI −1.14 to −0.23). VO2peak was statistically significantly
increased in women in the mainly exercise group by 198
ml/min (95 % CI 137–260) versus the control group and
by 32.0 ml/min (95 % CI −29.9 to 93.8) compared withSex Hormones and Physical Exercise (SHAPE)-2 study participants.
of the study and who did not participate in follow-up measurements.
rom the study prematurely, but who attended follow-up measurements.
Table 3 Baseline and 16-week differences in body composition and fitness between study groups
Baseline
mean
16-wk
mean
Change
at 16 wk
Percent
change
at 16 wk
Treatment effecta (95 % CI),
intervention vs control
P value* Treatment effecta (95 % CI),
mainly exercise vs diet
P value**
Body weight (kg)
Control 80.4 80.4 0.06 0.07
Diet 80.3 75.4 −4.89 −6.09 −4.95 (−5.69 to −4.21) <0.001
Mainly exercise 80.4 74.9 −5.52 −6.87 −5.58 (−6.32 to −4.84) <0.001 −0.63 (−1.23 to −0.04) 0.037
BMI (kg/m2)
Control 29.3 29.4 0.02 0.08
Diet 29.2 27.5 −1.78 −6.07 −1.80 (−2.06 to −1.53) <0.001
Mainly exercise 29.0 27.0 −2.00 −6.88 −2.02 (−2.29 to −1.75) <0.001 −0.22 (−0.44 to −0.01) 0.044
Waist circumference (cm)
Control 98.6 97.9 −0.66 −0.67
Diet 97.9 92.7 −5.14 −5.25 −4.54 (−5.76 to −3.33) <0.001
Mainly exercise 97.5 91.6 −5.97 −6.12 −5.40 (−6.62 to 4.18) <0.001 −0.86 (−1.84 to 0.13) 0.087
Hip circumference (cm)
Control 109.2 109.6 0.35 0.32
Diet 109.9 105.9 −3.99 −3.63 −4.31 (−5.30 to −3.32) <0.001
Mainly exercise 109.1 104.8 −4.31 −3.95 −4.67 (−5.65 to −3.68) <0.001 −0.36 (−1.15 to 0.44) 0.377
Body fat percentage (%)
Control 43.5 43.7 0.22 0.50
Diet 44.0 41.5 −2.54 −5.76 −2.82 (−3.54 to −2.11) <0.001
Mainly exercise 43.9 39.8 −4.11 −9.38 −4.38 (−5.10 to −3.67) <0.001 −1.56 (−2.14 to −0.98) <0.001
Total body fat (kg)
Control 33.8 34.0 0.17 0.49
Diet 34.0 30.3 −3.70 −10.89 −3.87 (−4.60 to −3.14) <0.001
Mainly exercise 34.0 28.8 −5.13 −15.11 −5.30 (−6.03 to −4.56) <0.001 −1.43 (−2.02 to −0.84) <0.001
Lean mass (kg)
Control 43.3 43.2 −0.10 −0.22
Diet 42.9 42.1 −0.78 −1.82 −0.71 (−1.14 to −0.23) <0.001
Mainly exercise 43.0 43.0 −0.06 −0.14 0.02 (−0.42 to 0.46) 0.930 0.73 (0.38–1.08) <0.001
VO2peak (ml/min)
Control 1761 1682 −78.6 −4.46
Diet 1752 1707 −44.9 −2.56 32.0 (−29.9 to 93.8) 0.310
Mainly exercise 1766 1885 118.7 6.72 198.4 (136.6–260.1) <0.001 166.4 (116.8–216.0) <0.001
SQUASH moderate and
vigorous activityb (min/wk)
Control 270 300 −30.0 −11.1
Diet 184 170 −14.0 −7.6 −82.6 (−263.8 to 98.6) 0.370
Mainly exercise 248 495 247 99.6 221.7 (42.9–400.5) 0.015 304.3 (157.9–450.7) <0.001
Baseline and follow-up measurements of complete cases (i.e. women with both baseline and follow-up measurements) are presented. Complete case data of
weight, BMI and waist and hip circumferences were available for 232 women; fat mass (kg and %) and lean mass for 230 women; VO2peak for 219 women; and
SQUASH for 206 women
Abbreviations: BMI body mass index, CI confidence interval, SQUASH Short Questionnaire to Assess Health-Enhancing Physical Activity, VO2peak peak oxygen uptake
*P < 0.025 was considered significant for the comparison of both intervention groups vs control
**P < 0.05 was considered significant for the comparison mainly exercise vs diet
aTreatment effect (95 % confidence interval) is the regression coefficient of a linear regression analysis
bBased on the SQUASH physical activity questionnaire, activities performed ≥4 metabolic equivalents
van Gemert et al. Breast Cancer Research  (2015) 17:120 Page 7 of 12
van Gemert et al. Breast Cancer Research  (2015) 17:120 Page 8 of 12the diet group. Moderate to vigorous physical activity ac-
cording to the SQUASH questionnaire also increased in
the mainly exercise group by 222 min/wk (95 % CI 43–
401) compared with the control arm and by 304 min/wk
(95 % CI 158–451) compared with the diet group.
Sex hormone outcomes
In our primary comparison, exercise versus diet-induced
weight loss, the mainly exercise group showed larger
treatment effects (Table 4). Statistically significantlyTable 4 Baseline and 16-week differences in serum sex hormones a
Baseline geometric
mean
Geometric mean
at 16 wk
Change
at 16 wk,
Oestradiol (pg/ml)
Control 3.89 4.01 3.11
Diet 4.20 3.62 −13.8
Mainly exercise 3.69 3.22 −12.7
Oestrone (pg/ml)
Control 20.1 20.4 1.51
Diet 20.4 20.1 −1.26
Mainly exercise 19.9 18.5 −6.67
Free oestradiol (pg/ml)
Control 0.09 0.10 3.23
Diet 0.10 0.08 −17.7
Mainly exercise 0.09 0.07 −19.1
Testosterone (pg/ml)
Control 194 186 −4.07
Diet 197 189 −3.76
Mainly exercise 186 172 −7.63
Androstenedione (pg/ml)
Control 575 560 −2.60
Diet 562 537 −4.50
Mainly exercise 573 488 −14.7
Free testosterone (pg/ml)
Control 2.71 2.61 −3.90
Diet 2.53 2.25 −11.2
Mainly exercise 2.44 2.01 −17.7
SHBG (nmol/L)
Control 44.2 44.0 −0.30
Diet 50.7 57.1 12.6
Mainly exercise 49.3 58.6 19.0
Baseline and follow-up measurements of complete cases (i.e., women with both ba
oestradiol were available for 223 women; oestrone for 221 women; free oestradiol f
testosterone for 228 women; and SHBG for 230 women
Abbreviations: CI confidence interval, SHBG sex hormone-binding hormone, TER trea
*P < 0.025 was considered significant for the comparison of both intervention grou
**P < 0.05 was considered significant for the comparison mainly exercise vs diet
aTER represents the overall intervention effect on hormone change (adjusted for ba
models were based on log-transformed hormone data, the presented treatment eff
that indicates how many times the level in one group is higher (TER >1) or lower (T
indicates that the hormone level in the intervention group is, on average, 10 % lowlarger effects were found for free testosterone (TER 0.92,
95 % CI 0.85–0.99), and borderline statistically signifi-
cant effects were seen for androstenedione (TER 0.90,
95 % CI 0.80–1.01) and SHBG (TER 1.05, 95 % CI 1.00–
1.12) (Table 4).
When we compared both intervention groups with the
control group, our secondary comparison, we found that
all hormone levels had decreased and SHBG had in-
creased (beneficial), except for testosterone in the diet
group (Table 4). Of these changes, statistically significantnd treatment effects between study groups
%
TERa (95 % CI),
intervention vs control
P value* TERa (95 % CI),
mainly exercise vs diet
P value**
0.86 (0.75–0.98) 0.025
0.83 (0.73–0.95) 0.007 0.97 (0.87–1.08) 0.562
0.98 (0.88–1.08) 0.650
0.92 (0.82–1.02) 0.109 0.94 (0.86–1.02) 0.154
0.80 (0.70–0.92) 0.002
0.77 (0.67–0.88) <0.001 0.96 (0.85–1.07) 0.425
1.01 (0.92–1.10) 0.886
0.96 (0.87–1.05) 0.332 0.95 (0.88–1.02) 0.166
0.97 (0.85–1.12) 0.684
0.87 (0.76–1.00) 0.059 0.90 (0.80–1.01) 0.064
0.91 (0.83–1.01) 0.069
0.84 (0.76–0.93) 0.001 0.92 (0.85–0.99) 0.043
1.14 (1.07–1.23) <0.001
1.21 (1.12–1.30) <0.001 1.05 (1.00–1.12) 0.070
seline and follow-up measurements) are presented. Complete case data of
or 222 women; testosterone and androstenedione for 229 women; free
tment effect ratio
ps vs control
seline), estimated by linear regression analysis. Because the linear regression
ect is the antilogarithm of the original estimate. Therefore, the TER is a ratio
ER <1) than a reference group. For example, TER intervention vs control of 0.9
er than in the control group
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SHBG in both the diet and mainly exercise groups and
for free testosterone in the mainly exercise group. Bor-
derline statistically significant changes were found for
free testosterone in the diet group versus the control
group and for androstenedione in the mainly exercise
group versus the control group.
After adjustment for changes in body fat percentage, the
observed intervention effects on (free) oestradiol, oestrone,
free testosterone and SHBG were attenuated or disap-
peared (Additional file 1). Only for androstenedione were
the additional effects of exercise versus diet not substan-
tially changed (TER 0.90, 95 % CI 0.79–1.01; P = 0.071).
In a secondary analysis of women who lost more than
2 kg (intervention groups) or remained weight-stable
(control group) (n = 206), results on sex hormones and
SHBG were comparable to those in the intention-to-
treat analysis (Additional file 2). A per-protocol analysis
of women adherent to the exercise prescription (n = 168)
showed larger intervention effects on all hormones. We
defined adherence as >80 % attendance at all exercise clas-
ses for the mainly exercise group. For the diet and control
groups, adherence was defined as <60 min/wk increase in
moderate to vigorous activities (≥4 MET), based on the
SQUASH questionnaire or, if missing, on the ActiGraph
activity monitor data.
The additional effect of exercise on SHBG compared
with diet increased to a significant level, whereas the
additional effects of androstenedione and free testoster-
one disappeared (Additional file 3).
Discussion
We found that, in postmenopausal women, 6–7 % weight
loss induced mainly by exercise resulted in a more
favourable body composition (i.e., larger loss of body fat
and preservation of lean mass), better physical fitness and
larger effects on free testosterone, as well as suggestive ef-
fects for androstenedione and SHBG compared with a
similar amount of weight loss induced by following a
hypocaloric diet only. The exercise intervention consisted
of a combination of endurance and strength training. Fur-
thermore, both weight loss interventions resulted in sig-
nificant favourable effects on oestradiol, free oestradiol,
androstenedione (exercise only), free testosterone and
SHBG compared with the control group. After adjustment
for changes in body fat, most intervention effects were at-
tenuated or disappeared. These findings support the hy-
pothesis that the greater loss of body fat induced by
exercise compared with diet largely mediates the effects of
physical activity on sex hormones.
A modest and sustained body weight reduction of 3–5 %
has been shown to result in clinically meaningful improve-
ments in health, and the degree of weight loss is directly
proportional to health benefits regarding cardiovascularoutcomes [30]. Large cohort studies also suggest that
modest weigh loss (5–10 %) results in breast cancer risk
reductions of 25–50 % [31, 32]. Our results show that a
reduction in body fat, more than a decrease in body
weight in general, is an important factor in inducing
changes in sex hormones. These findings contribute to the
body of evidence in this field derived from the previous
exercise or weight loss intervention studies in postmeno-
pausal women [8–10, 33] and to the understanding of the
underlying mechanisms connecting physical activity and
decreased breast cancer risk. After menopause, fat tissue
is the most important source of oestrogens because the
enzyme aromatase, present in adipose tissue, converts an-
drogens to oestrogens [34]. Furthermore, abdominal fat is
associated with higher levels of insulin, inhibiting SHBG
production [35, 36]. In our study, both intervention
groups experienced a decrease in fat tissue, but more so in
the mainly exercise group than in the diet group, despite
comparable weight loss. The fat loss induced a decrease in
sex steroid hormone levels and an increase in SHBG,
resulting in less unbound and biologically active oestradiol
and testosterone. Two randomised, low-fat dietary inter-
vention studies demonstrated small weight losses (3–6 %),
and these trials also showed significant improvements in
SHBG [37, 38] and testosterone [37], but not in oestradiol.
A study comparable to ours is the Nutrition and Exer-
cise for Women (NEW) trial, a 12-month study of post-
menopausal women in the United States in which
researchers are investigating the combined and individ-
ual effects of a diet and aerobic exercise intervention on
sex hormones [39]. Unlike SHAPE-2, the aim of that
trial was not equivalent weight loss, and SHAPE-2 also in-
cluded resistance training in addition to aerobic exercise.
In the NEW trial, the combined exercise and diet group
(most comparable to our mainly exercise group) had the
largest losses in body weight (−9.8 kg) and body fat
(−6.4 %), whereas diet alone resulted in −9.1 kg weight
loss and −5.0 % fat loss [39]. In the exercise-alone
group, these figures were −2.8 kg and −2.1 %, respect-
ively. All three intervention groups showed significant
effects on sex hormones compared with the control
group. The exercise-only group showed the smallest ef-
fects. The diet and the diet with exercise group showed
larger changes in sex hormones. Except for the changes
in androgens, changes in oestrogens and SHBG in the
NEW diet intervention groups were larger than in our
study (5–10 % difference on average). For example, free
oestradiol was reduced 21 % in the NEW diet group ver-
sus 18 % in our diet group and by 26 % in the NEW diet
with exercise group versus 19 % in our mainly exercise
group. These findings are in agreement with their larger
losses in fat mass compared with the SHAPE-2 data, in-
dicating a dose–response relationship for oestrogens.
However, in the NEW trial, none of the differences
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reached statistical significance.
We found additional effects of exercise compared with
diet alone on androgens and SHBG. For oestrogens, we ob-
served small differences (3–4 %) that were not statistically
significant. Our study was powered to detect a difference
of 8 % as a minimum, which could explain the non-
significance of these findings. The NEW trial researchers
concluded that greater weight loss produced stronger ef-
fects on oestrogens and SHBG. The SHAPE-2 trial adds to
their conclusion that, more specifically, fat loss produces
stronger effects on sex hormones, including androgens.
Losing weight mainly by exercise instead of by diet
alone resulted in a larger loss of fat, the target tissue for
relevant biomarkers, and preservation of lean body mass,
which is important for prevention of other chronic dis-
eases. It is known that sarcopenia, characterised by a
loss of lean mass, often affects elderly persons and is re-
sponsible for high morbidity and mortality [40].
Exercise can be roughly divided into two types: endur-
ance and strength training. Endurance training is most
likely to result in weight loss [41]. However, especially
strength training is associated with a more favourable
body composition regarding total fat and muscle mass
[17, 41]. Therefore, to achieve weight reduction, we rec-
ommend a combination of diet with exercise, supporting
current recommendations on lifestyle behaviour change
to reduce obesity [42, 43].
To our knowledge, no previous researchers have re-
ported on effects of strength training alone on sex hor-
mones in postmenopausal women. In our study, all
women in the mainly exercise group engaged in both
types of exercise; thus, we are not able to disentangle
separate effects of endurance and strength training.
Most observational studies show an independent effect
of physical activity, after adjusting for body weight, on
breast cancer risk [1, 44, 45]. Some also have found an
independent effect on serum sex hormones [46, 47]. This
may reflect residual confounding because adjustment for
weight or BMI does not fully cover the adjustment for fat,
the most relevant tissue. Another explanation is that exer-
cise affects other breast cancer risk–related mechanisms
which are not (fully) fat-dependent, such as insulin sensi-
tivity or the immune system and inflammation [5].
The direct impact of our study results on breast cancer
risk remains speculative. We used aromatase inhibitor
and BMI studies to estimate the clinical impact. Aroma-
tase inhibitors reduce oestradiol by 83–89 % in patients
with breast cancer [48–50], whereas researchers in two
randomised trials in healthy high-risk women observed a
53–65 % breast cancer risk reduction associated with
these drugs during 5 years of follow-up [51, 52]. Ex-
trapolating these data to our study, wherein we observed
a 13 % decrease in oestradiol, would reveal an 8–10 %reduction in breast cancer risk. The observed two-unit
reduction in BMI as a starting point would reduce breast
cancer risk by approximately 5 % because every five-unit
gain in BMI shows a relative risk of 1.13 [1]. Although
these different estimation methods and cohort studies
[31, 32] indicate a 5–10 % risk reduction, the direct and
long-term impacts of weight loss on breast cancer risk
are still unclear, leaving a challenge for future research.
Our study has several strengths. First, we used a strong
design with the unique aim of reaching comparable weight
loss between the two intervention groups, which was
largely accomplished in both groups. In addition, our
study design incorporated a run-in period during which
all women were prescribed a standardised diet. Therefore,
food components that might potentially influence sex hor-
mones, such as alcohol and dietary fibre, are unlikely to
have affected the results. Another strength is the high
adherence to the study protocol in all three groups. Ad-
herence of the control group is often challenging in
lifestyle-related trials [53]; therefore, we offered an alterna-
tive weight loss programme after trial completion. Finally,
we used the LC-MS method, which is the reference stand-
ard because it is a highly sensitive technique to measure
hormone levels that is less prone to cross-reactions [54, 55].
There are also some limitations which we need to ac-
knowledge. Despite the fact that both intervention
groups achieved the weight loss target, there was a dif-
ference of 0.6 kg in favour of the mainly exercise group.
Although this is a clinically small difference, it may have
affected the outcomes related to the exercise–diet com-
parison slightly. However, the difference in fat loss we
observed to be most influential on sex hormones was
much larger between the two groups. Furthermore, as
weight loss represents mainly fat loss, additional adjust-
ment for weight change has no added value.
Conclusions
We found that a modest reduction in body weight (6–7 %)
either by following a hypocaloric diet or mainly by exercise
led to beneficial effects on sex hormones and SHBG.
Moreover, this amount of weight loss induced mainly by
exercise led to a more favourable body composition (less
fat and preservation of lean mass) and free testosterone,
androstenedione (lower) and SHBG (higher). Body fat
largely mediated the effects of exercise on these hormones,
suggesting that fat loss in particular is most important in
influencing sex hormone levels which are associated with
postmenopausal breast cancer risk.
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